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Background
Red yeast rice is known to reduce serum LDL and total cholesterol levels. It has been repeatedly advocated as alternative therapy for statins (1, 2, 3) .
Monascus purpureus was utilized in the original production of lovastatin, the first marketed pharmaceutical statin (4, 5) . The lipid-regulating component of red yeast rice, monacolin K, is chemically identical to lovastatin. The identical properties account for the similarity in therapeutic and side effects of red yeast rice and lovastatin.
Objective
This presentation reviews red yeast rice's properties, my clinical experiences and others' clinical experiences which support the pitfalls of using this preparation in clinical practice.
Methods
A thorough literature search was conducted using online databases in addition to print publications. Controlled clinical trials of red yeast rice, conducted worldwide, in all languages, were used to contribute to the content of this paper. This paper is intended to review the efficacy and side effects noted within the red yeast rice clinical trials.
Reviews of Efficacy, Safety & Side-effects of Red Yeast Rice
Monacolins block the production of cholesterol. Since red yeast rice preparations rarely declare their monacolin K content, understanding dose-related efficacy and side-effect risks in red yeast rice is practically impossible.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
4
Statins may cause muscle injury with symptoms of increasing severity e.g. weakness, soreness and cramps, which can lead to kidney damage and renal failure. This is why statins are "by prescription only" in the United States -with recommendations to schedule safety tests on a regular basis.
Red yeast rice has been reported to occasionally have the same serious side effects as statins including myopathy, rhabdomyolysis, and hepatotoxicity. To complicate matters further, different batches of red yeast rice crops may contain citrinin and additional toxic chemicals if they are grown with insecticides and/or pesticides.
Up to 80% of red yeast rice products were found to contain high levels of the nephrotoxic mycotoxin citrinin. Gordon, et al, tested for citrinin levels in 12 commercial red yeast rice preparations; they found a 0-119 ppm range in citrinin content (6) . In patients receiving red yeast rice, the potential nephrotoxicity by citrinin can lead to renal failure (7).
It would be ideal to perform controlled clinical trials with several commercial red yeast rice products. However, those trials would be futile and un-interpretable until the FDA conducts inspection and issues rules on standardization of red yeast rice's preparation products. Gordon, et al, evaluated monacolin levels in 12 commercial red yeast rice preparations.
They found up to an 11-fold difference in the concentration of monacolin K among red yeast rice preparations (6) .
Pharmaceutical Regulatory Issues
Red yeast rice is a yeast extracted from red rice; the extraction methods are not As stated by Childress, et al, and Becker, et al, a total of 101 and 12 products respectively containing red yeast rice were reviewed (2,9). They noted: a) no product could be confirmed as passing independent laboratory verification testing, b) 42.6% of red yeast rice product labels contained statin-related warnings (i.e, muscle pain, weakness, etc) (9), c) many products avoid FDA restrictions by declaring no monacolin content, d) labels and websites said no more than "fermented according to traditional Asian methods" or "similar to that used in culinary applications", e) labeling often says nothing about efficacy on cholesterol levels, and f) if they do not claim to contain lovastatin or to lower cholesterol, they are not subject to FDA regulations.
There was no information regarding absence, presence and/or concentration of monacolin K. They confirmed that the monacolin content of red yeast rice dietary supplements varies over a wide range, with some containing negligible amounts and types of monacolins and others containing several monacolins at various concentrations.
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The use of red yeast rice in patients with statin intolerance has been advocated based on trials finding no replication of myositis after red yeast rice administration to such patients (9). This conclusion disregards the frequent occurrence of no replication of myositis in 11-70% of patients after challenge with the same statin which caused the myositis; these data were also derived from controlled clinical trials. (10) Despite multiple reports of relatively satisfactory efficacy and safety of red yeast rice preparations (9, 11) , over-the-counter preparations are not as standardized and pure as the preparation of lovastatin made by reputable pharmaceutical companies. Therefore, it will be possible that some, if not all, red yeast rice preparations will have issues of unpredictable therapeutic efficacy and/or side effects. Since differences in composition of red yeast rice were found among such products made in the USA, (6) the differences might be equal or larger in products from outside the USA.
My experience with lovastatin used under placebo-controlled clinical trials
Before red yeast rice preparations existed in the market, my lipid research clinic at the University of Kansas was one of the sites for the largest multicenter placebo controlled phase IV study (12) with Lovastatin (Mevacor, TM). Because of the above precedent, we were commissioned by a Chinese producer of red yeast rice to perform a clinical trial use of red yeast rice in patients with hypercholesterolemia. This sponsor intended to obtain FDA approval to sell red yeast rice supplement as an OTC naturopathic medicine. The study was an informed-consent, double-blind placebo-controlled in 80 patients, half of them on a 600 mg red yeast rice capsule and half of them on identical-looking placebo capsules. The trial was approved by the University of Kansas IRB (data not published due to its non-proprietary nature).
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Results
The efficacy and side effects results were similar to those of my previous study (12) with the lovastatin 20-40 mg doses' preparation from Merck (Mevacor). However, the FDA had justifiable concerns regarding the reproducibility of results with unregulated red yeast rice preparations in general, as they existed or could become part of the OTC market. For this reason, approval was denied.
Discussion and Conclusions
There are many publications attesting to the LDL-lowering properties of red yeast rice preparations. Epidemiological data of areas in China where red rice consumption is prevalent indicate lower incidence of atherosclerotic cardiovascular disease (3, 11, 13, 14, 15, 16) . These observations seem to justify using red yeast rice as a substitution for statins. 
